AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03431168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/TMPS
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
Study NCT00809757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: 90 ug Levalbuterol (2 actuations)
Study NCT00809757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levalbuterol UDV TID
Description: 0.31 ug Levalbuterol UDV TID
Study NCT00809757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 actuations)
Study NCT00924950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex Ointment and Hydrogel Patch
Description: Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
Study NCT00924950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex Ointment
Description: Taclonex ointment daily for one psoriatic plaque.
Study NCT01053858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
Study NCT04121728 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ginkgo biloba extract
Description: Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
Study NCT04121728 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
Study NCT00557115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation (EPR)
Description: Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
Study NCT00610194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA119
Description: In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
Study NCT01233089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens, investigational
Description: Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
Study NCT01233089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)
Description: Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
Study NCT01233089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)
Description: Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
Study NCT01233089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care system (ClearCare)
Description: Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
Study NCT01233089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (ClearCare)
Description: Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
Study NCT04364035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.HTI
Description: ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
Study NCT04364035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HTI
Description: MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
Study NCT04364035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9620
Description: GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
Study NCT00950001 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT03047031 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study NCT03047031 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone
Study NCT03343054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
Study NCT03169660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor trap-eye
Description: Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
Study NCT04331418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
Study NCT04331418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caudal block
Description: After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
Study NCT00364273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159802
Description: GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
Study NCT00364273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo administered using DISKUS inhaler.
Study NCT00364273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
Study NCT01614808 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03111407 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: total knee arthroplasty
Description: surgical procedure in which damaged parts of the knee joint are replaced with an implant.
Study NCT04639739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR NK
Description: 2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
Study NCT04615286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short course (2-3 weeks) of antibiotics
Description: Shorter course of antibiotic than standard care of 4-6 weeks
Study NCT04615286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (long course) of antibiotics
Description: 4-6 weeks of antibiotics
Study NCT02574507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples-Based Behavioral Weight and Symptom Management
Description: Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
Study NCT03095963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)
Description: Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
Study NCT03095963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxin
Description: replacement therapy for hypothyroidism
Study NCT04341207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg 3 times a day for 10 days
Study NCT04341207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
Study NCT00871104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin and imipenem
Description: IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
Study NCT00871104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
Study NCT04688814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single puncture combined lumbar erector spinae plane block and quadrates lumborum block
Description: Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM.
Study NCT04688814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
Study NCT00881595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy Temozolomide
Description: Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
Study NCT00881595 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton therapy
Description: 50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
Study NCT00881595 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proton Chemoradiotherapy followed by surgery
Description: Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
Study NCT00359424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV rt-PA alone
Description: Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
Study NCT00359424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endovascular therapy
Description: Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
Study NCT03758664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,
Study NCT02041819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
Study NCT02949973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin
Study NCT00695604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via MDI.
Study NCT00695604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone MDI.
Study NCT00894972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation following lumbar disc surgery (discectomy)
Description: Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
Study NCT00894972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation following lumbar disc surgery (discectomy)
Description: Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
Study NCT04849403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CTSP
Description: In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
Study NCT03440242 — intervention group
Intervention type: DEVICE
Intervention: JJVC Contact Lens
Description: etafilcon A with PVP DD
Study NCT03440242 — intervention group
Intervention type: DEVICE
Intervention: Marketed Contact Lens
Description: nelfilcon A DD
Study NCT01701011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping intervention
Description: Positive reappraisal coping intervention
Study NCT03228979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Semi-Interactive Stroke Prevention Package
Description: The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
Study NCT00648882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVOTHYROXINE SODIUM TABLETS,
Description: 2x300mcg, single dose fasting
Study NCT00648882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYNTHROID® 300 mcg Tablets
Description: 2x300mcg, single dose fasting
Study NCT01052480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Influenza Immune Plasma
Description: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Study NCT01052480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
Study NCT01052480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
Study NCT02859337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: UPA-ECx1
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
Study NCT02859337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UPA-ECx1
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
Study NCT02859337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPA-ECx1
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
Study NCT02859337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UPA-ECx2
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
Study NCT02859337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPA-ECx2
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
Study NCT03920124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step and walk-based high intensity interval exercise
Description: Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of \~30 min daily or \~150 min weekly).
Study NCT02088762 — intervention group
Intervention type: PROCEDURE
Intervention: surgical excision
Description: comparison of safety margin 1 versus 2 cm
Study NCT02481089 — intervention group
Intervention type: OTHER
Intervention: validation group
Study NCT04969679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli Nissle 1917 (Mutaflor®)
Description: Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
Study NCT04969679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
Study NCT01065961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron
Description: Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
Study NCT01065961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
Study NCT01041937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Tibia
Description: Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
Study NCT01041937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless Tibia
Description: Assessing the clinical outcomes of the different type of fixation
Study NCT00684216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 200 mg, BID, PO, QD until progression of disease
Study NCT00684216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
Description: either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
Study NCT02498665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
Study NCT03891810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm
Description: The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts).
Study NCT03579836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
Study NCT03579836 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.